Research Paper Volume 13, Issue 17 pp 21671—21699

Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer

Association of TfR1 expression with clinicopathological parameters of BC patients. TfR1 expression was investigated in (A) female (n = 1075) and male (n = 12) patients, (B) patients with different stages of BC (normal individuals, n = 114; stage 1, n = 183; stage 2, n = 615; stage 3, n = 247; and stage 4, n = 20), (C) patients with different nodal metastasis statuses (normal individuals, n = 114; N0, n = 516; N1, n = 362; N2, n = 120; and N3, n = 77), (D) patients with different TP53 mutation statuses (normal individuals, n = 114; TP53-nonmutant, n = 698; and TP53-mutant, n = 334), (E) patients with different BC subtypes (normal individuals, n = 114; HER-positive, n = 37; luminal, n = 566; and triple negative, n = 116) and (F) patients with different ages (normal individuals, n = 114; 21–40 years, n = 97; 41–60 years, n = 505; 61–80 years, n = 431; and 81–100 years, n =54). ******

Figure 3. Association of TfR1 expression with clinicopathological parameters of BC patients. TfR1 expression was investigated in (A) female (n = 1075) and male (n = 12) patients, (B) patients with different stages of BC (normal individuals, n = 114; stage 1, n = 183; stage 2, n = 615; stage 3, n = 247; and stage 4, n = 20), (C) patients with different nodal metastasis statuses (normal individuals, n = 114; N0, n = 516; N1, n = 362; N2, n = 120; and N3, n = 77), (D) patients with different TP53 mutation statuses (normal individuals, n = 114; TP53-nonmutant, n = 698; and TP53-mutant, n = 334), (E) patients with different BC subtypes (normal individuals, n = 114; HER-positive, n = 37; luminal, n = 566; and triple negative, n = 116) and (F) patients with different ages (normal individuals, n = 114; 21–40 years, n = 97; 41–60 years, n = 505; 61–80 years, n = 431; and 81–100 years, n =54). *< 0.05, **< 0.01, ***< 0.001.